Cargando…

Animal models of osteogenesis imperfecta: applications in clinical research

Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a genetic disease characterized by extreme bone fragility and consequent skeletal deformities. This connective tissue disorder is caused by mutations in the quality and quantity of the collagen that in turn affect the overall m...

Descripción completa

Detalles Bibliográficos
Autores principales: Enderli, Tanya A, Burtch, Stephanie R, Templet, Jara N, Carriero, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209373/
https://www.ncbi.nlm.nih.gov/pubmed/30774469
http://dx.doi.org/10.2147/ORR.S85198
_version_ 1783366900675248128
author Enderli, Tanya A
Burtch, Stephanie R
Templet, Jara N
Carriero, Alessandra
author_facet Enderli, Tanya A
Burtch, Stephanie R
Templet, Jara N
Carriero, Alessandra
author_sort Enderli, Tanya A
collection PubMed
description Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a genetic disease characterized by extreme bone fragility and consequent skeletal deformities. This connective tissue disorder is caused by mutations in the quality and quantity of the collagen that in turn affect the overall mechanical integrity of the bone, increasing its vulnerability to fracture. Animal models of the disease have played a critical role in the understanding of the pathology and causes of OI and in the investigation of a broad range of clinical therapies for the disease. Currently, at least 20 animal models have been officially recognized to represent the phenotype and biochemistry of the 17 different types of OI in humans. These include mice, dogs, and fish. Here, we describe each of the animal models and the type of OI they represent, and present their application in clinical research for treatments of OI, such as drug therapies (ie, bisphosphonates and sclerostin) and mechanical (ie, vibrational) loading. In the future, different dosages and lengths of treatment need to be further investigated on different animal models of OI using potentially promising treatments, such as cellular and chaperone therapies. A combination of therapies may also offer a viable treatment regime to improve bone quality and reduce fragility in animals before being introduced into clinical trials for OI patients.
format Online
Article
Text
id pubmed-6209373
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62093732019-02-15 Animal models of osteogenesis imperfecta: applications in clinical research Enderli, Tanya A Burtch, Stephanie R Templet, Jara N Carriero, Alessandra Orthop Res Rev Review Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a genetic disease characterized by extreme bone fragility and consequent skeletal deformities. This connective tissue disorder is caused by mutations in the quality and quantity of the collagen that in turn affect the overall mechanical integrity of the bone, increasing its vulnerability to fracture. Animal models of the disease have played a critical role in the understanding of the pathology and causes of OI and in the investigation of a broad range of clinical therapies for the disease. Currently, at least 20 animal models have been officially recognized to represent the phenotype and biochemistry of the 17 different types of OI in humans. These include mice, dogs, and fish. Here, we describe each of the animal models and the type of OI they represent, and present their application in clinical research for treatments of OI, such as drug therapies (ie, bisphosphonates and sclerostin) and mechanical (ie, vibrational) loading. In the future, different dosages and lengths of treatment need to be further investigated on different animal models of OI using potentially promising treatments, such as cellular and chaperone therapies. A combination of therapies may also offer a viable treatment regime to improve bone quality and reduce fragility in animals before being introduced into clinical trials for OI patients. Dove Medical Press 2016-09-27 /pmc/articles/PMC6209373/ /pubmed/30774469 http://dx.doi.org/10.2147/ORR.S85198 Text en © 2016 Enderli et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Enderli, Tanya A
Burtch, Stephanie R
Templet, Jara N
Carriero, Alessandra
Animal models of osteogenesis imperfecta: applications in clinical research
title Animal models of osteogenesis imperfecta: applications in clinical research
title_full Animal models of osteogenesis imperfecta: applications in clinical research
title_fullStr Animal models of osteogenesis imperfecta: applications in clinical research
title_full_unstemmed Animal models of osteogenesis imperfecta: applications in clinical research
title_short Animal models of osteogenesis imperfecta: applications in clinical research
title_sort animal models of osteogenesis imperfecta: applications in clinical research
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209373/
https://www.ncbi.nlm.nih.gov/pubmed/30774469
http://dx.doi.org/10.2147/ORR.S85198
work_keys_str_mv AT enderlitanyaa animalmodelsofosteogenesisimperfectaapplicationsinclinicalresearch
AT burtchstephanier animalmodelsofosteogenesisimperfectaapplicationsinclinicalresearch
AT templetjaran animalmodelsofosteogenesisimperfectaapplicationsinclinicalresearch
AT carrieroalessandra animalmodelsofosteogenesisimperfectaapplicationsinclinicalresearch